STAT+: Pharmalittle: FTC suspends challenge to Amgen deal for Horizon; AstraZeneca is latest to challenge Medicare drug negotiations

August 28, 2023 Los Angeles Biotechnology Network News Los Angeles Biotech News Comments Off on STAT+: Pharmalittle: FTC suspends challenge to Amgen deal for Horizon; AstraZeneca is latest to challenge Medicare drug negotiations

The U.S. Federal Trade Commission suspended its challenge to Amgen’s $27.8 billion acquisition of Horizon Therapeutics.
Click here to view original post